Non-coding RNAs show distinct expression patterns in dilated, hypertrophic, and arrhythmogenic cardiomyopathies, potentially serving as novel therapeutic targets and risk stratification models.
What is the role of non-coding RNAs in the etiopathogenesis and potential treatment of cardiomyopathies?
Non-coding RNAs are implicated in the molecular mechanisms of cardiomyopathies and represent potential future therapeutic targets and biomarkers for risk stratification.
Cardiomyopathies are the structural and functional disorders of the myocardium. Etiopathogenesis is complex and involves an interplay of genetic, environmental, and lifestyle factors eventually leading to myocardial abnormalities. It is known that non-coding (Nc) RNAs, including micro (mi)-RNAs and long non-coding (lnc) RNAs, play a crucial role in regulating gene expression. Several studies have explored the role of miRNAs in the development of various pathologies, including heart diseases. In this review, we analyzed various patterns of ncRNAs expressed in the most common cardiomyopathies: dilated cardiomyopathy, hypertrophic cardiomyopathy and arrhythmogenic cardiomyopathy. Understanding the role of different ncRNAs implicated in cardiomyopathic processes may contribute to the identification of potential therapeutic targets and novel risk stratification models based on gene expression. The analysis of ncRNAs may also be helpful to unveil the molecular mechanisms subtended to these diseases.
Carabetta et al. (Wed,) conducted a review in Cardiomyopathies. Non-coding RNAs was evaluated. Non-coding RNAs show distinct expression patterns in dilated, hypertrophic, and arrhythmogenic cardiomyopathies, potentially serving as novel therapeutic targets and risk stratification models.